In addition, it still remains unclear whether expression of PD-1 on tumor cells or on other nonmalignant cells is a key factor associated with clinical outcomes in response to PD-1/PD-L1 blockade in DLBCL. Here, PDCD1 is linked to diffuse large B-cell lymphoma.